NS

InspireMD IncNASDAQ NSPR Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.072

Micro

Exchange

XNAS - Nasdaq

NSPR Stock Analysis

NS

Uncovered

InspireMD Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

24/100

Low score

Market cap $B

0.072

Dividend yield

Shares outstanding

8.336 B

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

View Section: Eyestock Rating